Following an over 12% decline in the previous session in reaction to updates at the company’s R&D Day event, Moderna ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna Inc.’s shares (NASDAQ:MRNA) sank 19% to a $64.11 low in early trading Sept. 12 as investors learned during the annual ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Drug maker Moderna, Inc. (MRNA), at its annual R&D Day event on Thursday, presented its outlook for fiscal 2025 and beyond, as well ...

Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.

By investing heavily on EV R&D, India can further localise production to create more jobs, tap export markets to gain global ...

Houston Texans tight end Brevin Jordan reflected on playing the entirety of the team's 19-13 win over the Chicago Bears on Sunday before learning that ...